HALO (Halozyme Therapeutics) Cash per Share: $2.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HALO Halozyme Therapeutics Inc HALO
91 GF Score
Price $109.31
GF Value $98.05
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Cash per Share?

Halozyme Therapeutics HALO +0.63% 91 Cash per Share is $2.03 as of Jun. 2026. GuruFocus rates HALO with a GF Score™ of 91/100 and a GF Value™ of $98.05 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Halozyme Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 was $2.03.

Halozyme Therapeutics  (NAS:HALO) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Halozyme Therapeutics Cash per Share Related Terms

Halozyme Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Cash per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.39 2.68 2.65 4.84 1.21

Halozyme Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.66 5.97 1.21 2.69 2.03
HALO
91GF Score
Halozyme Therapeutics Inc HALO
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Halozyme Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=142.82/118
=1.21

Halozyme Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=231.003/114
=2.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $2.03 mean?
Halozyme Therapeutics (HALO) has a Cash per Share of $2.03 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Cash per Share too high?
Halozyme Therapeutics' current Cash per Share is $2.03. Overall, Halozyme Therapeutics has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cash per Share compare to NUVL and KRYS?
Halozyme Therapeutics' Cash per Share of $2.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Cash per Share is $2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Overvalued. The stock's GF Value™ is $98.05, compared to a current price of $109.31 — trading 11.5% above its estimated fair value. The current Cash per Share is $2.03. Halozyme Therapeutics' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Cash per Share is $2.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of $109.31 is trading 11.5% above its estimated GF Value™ of $98.05. GuruFocus considers Halozyme Therapeutics to be Modestly Overvalued.

Key valuation signals for HALO:

  • Cash per Share: $2.03
  • GF Value™: $98.05 vs. price of $109.31 (11.5% above fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
91GF Score

Get the complete analysis for HALO

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$109.31
Price
$98.05
GF Value